Levosimendan exerts anti-inflammatory effects on cardiac myocytes and endothelial cells in vitro

Thrombosis and Haemostasis

Volumn 113, Issue 2, 2015, Pages 350-362

  Krychtiuk, Konstantin A ^a,b   Watzke, Lukas ^a   Kaun, Christoph ^a   Buchberger, Elisabeth ^a   Hofer Warbinek, Renate ^a   Demyanets, Svitlana ^a   Pisoni, Julia ^a,b   Kastl, Stefan P ^a   Rauscher, Sabine ^a,c   Gröger, Marion ^a,c   Aliabadi, Arezu ^a   Zuckermann, Andreas ^a   Maurer, Gerald ^a   de Martin, Rainer ^a   Huber, Kurt ^b,d   Wojta, Johann ^a,b   Speidl, Walter S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Ludwig Boltzmann Cluster for Cardiovascular Research   (Austria)

^c Universitatsklinik fur Dermatologie   (Austria)

^d WILHELMINEN HOSPITAL   (Austria)

Author keywords

Cardiac myocytes; Endothelial cells; Granulocytes; Levosimendan; Myocardial infarction

Indexed keywords

5 HYDROXYDECANOIC ACID; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; COMPLEMENTARY DNA; DICHLOROFLUORESCEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FLUORESCEIN ISOTHIOCYANATE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G1 ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; LEVOSIMENDAN; MESSENGER RNA; MONOCLONAL ANTIBODY; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 1BETA; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; 5-HYDROXYDECANOIC ACID; ANTIINFLAMMATORY AGENT; DECANOIC ACID DERIVATIVE; HYDRAZONE DERIVATIVE; HYDROXYACID; INTERLEUKIN 1BETA; PYRIDAZINE DERIVATIVE; SIMENDAN; VASODILATOR AGENT;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CAPILLARY ENDOTHELIAL CELL; CELL ADHESION ASSAY; CELL COUNT; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE NECROSIS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; MRNA EXPRESSION ASSAY; NEUTROPHIL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; RNA PURIFICATION; WESTERN BLOTTING; CELL ADHESION; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; HEART FAILURE; INFLAMMATION; METABOLISM; MICROCIRCULATION; MUSCLE CELL; NECROSIS; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANTI-INFLAMMATORY AGENTS; CELL ADHESION; CELLS, CULTURED; DECANOIC ACIDS; E-SELECTIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEART FAILURE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDRAZONES; HYDROXY ACIDS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKIN-8; MICROCIRCULATION; MICROSCOPY, FLUORESCENCE; MUSCLE CELLS; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; NECROSIS; NEUTROPHILS; NF-KAPPA B; PHOSPHORYLATION; PYRIDAZINES; REACTIVE OXYGEN SPECIES; VASODILATOR AGENTS;

EID: 84922475941     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-06-0549     Document Type: Article

References (36)

1. Papp Z, Edes I, Fruhwald S, et al. Levosimendan: Molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol 2012; 159: 82-87.
2. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360: 196-202.
3. Packer M, Colucci W, Fisher L, et al. Effect of Levosimendan on the Short-Term Clinical Course of Patients With Acutely Decompensated Heart Failure. JACC: Heart Failure 2013; 1: 103-111.
4. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. J Am Med Assov 2007; 297: 1883-1891.
5. Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002; 23: 1422-1432.
6. Husebye T, Eritsland J, Muller C, et al. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. Eur J Heart Fail 2013; 15: 565-572.
7. Maharaj R, Metaxa V. Levosimendan and mortality after coronary revascularisation: a meta-analysis of randomised controlled trials. Crit Care 2011; 15: R140.
8. Du Toit EF, Muller CA, McCarthy J, et al. Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischaemia/reperfusion in the Langendorff-perfused guinea pig heart. J Pharmacol Exp Ther 1999; 290: 505-514.
9. Kersten JR, Montgomery MW, Pagel PS, et al. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg 2000; 90: 5-11.
10. Lepran I, Pollesello P, Vajda S, et al. Preconditioning effects of levosimendan in a rabbit cardiac ischaemia-reperfusion model. J Cardiovasc Pharmacol 2006; 48: 148-152.
11. Pollesello P, Papp Z. The cardioprotective effects of levosimendan: preclinical and clinical evidence. J Cardiovasc Pharmacol 2007; 50: 257-263.
12. Kopustinskiene DM, Pollesello P, Saris NE. Levosimendan is a mitochondrial K(ATP) channel opener. Eur J Pharmacol 2001; 428: 311-314.
13. Oldenburg O, Cohen MV, Yellon DM, et al. Mitochondrial K(ATP) channels: role in cardioprotection. Cardiovasc Res 2002; 55: 429-437.
14. Uberti F, Caimmi PP, Molinari C, et al. Levosimendan modulates programmed forms of cell death through K(ATP) channels and nitric oxide. J Cardiovasc Pharmacol 2011; 57: 246-258.
15. Grossini E, Molinari C, Caimmi PP, et al. Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial K(ATP) channel. Br J Pharmacol 2009; 156: 250-261.
16. Hasslacher J, Bijuklic K, Bertocchi C, et al. Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: a prospective observational study. Crit Care 2011; 15: R166.
17. Frohlich GM, Meier P, White SK, et al. Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J 2013; Epub ahead of print.
18. Gwechenberger M, Mendoza LH, Youker KA, et al. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation 1999; 99: 546-551.
19. Kyrzopoulos S, Adamopoulos S, Parissis JT, et al. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central haemodynamics in severe heart failure patients. Int J Cardiol 2005; 99: 409-413.
20. Sareila O, Korhonen R, Auvinen H, et al. Effects of levo-and dextrosimendan on NF-kappaB-mediated transcription, iNOS expression and NO production in response to inflammatory stimuli. Br J Pharmacol 2008; 155: 884-895.
21. Revermann M, Schloss M, Mieth A, et al. Levosimendan attenuates pulmonary vascular remodeling. Intensive Care Med 2011; 37: 1368-1377.
22. Rychli K, Kaun C, Hohensinner PJ, et al. The inflammatory mediator oncostatin M induces angiopoietin 2 expression in endothelial cells in vitro and in vivo. J Thromb Haemost 2010; 8: 596-604.
23. Demyanets S, Konya V, Kastl SP, et al. Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2011; 31: 2080-2089.
24. Macfelda K, Weiss TW, Kaun C, et al. Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1alpha, tumor necrosis factor-alpha, transforming growth factor-beta and oncostatin M in human cardiac myocytes. J Mol Cell Cardiol 2002; 34: 1681-1691.
25. Hohensinner PJ, Kaun C, Rychli K, et al. Monocyte chaemoattractant protein (MCP-1) is expressed in human cardiac cells and is differentially regulated by inflammatory mediators and hypoxia. FEBS Lett 2006; 580: 3532-3538.
26. Weiss TW, Kvakan H, Kaun C, et al. The gp130 ligand oncostatin M regulates tissue inhibitor of metalloproteinases-1 through ERK1/2 and p38 in human adult cardiac myocytes and in human adult cardiac fibroblasts: a possible role for the gp130/gp130 ligand system in the modulation of extracellular matrix degradation in the human heart. J Mol Cell Cardiol 2005; 39: 545-551.
27. Kastl SP, Speidl WS, Kaun C, et al. In human macrophages the complement component C5a induces the expression of oncostatin M via AP-1 activation. Arterioscler Thromb Vasc Biol 2008; 28: 498-503.
28. Brostjan C, Anrather J, Csizmadia V, et al. Glucocorticoids inhibit E-selectin expression by targeting NF-kappaB and not ATF/c-Jun. J Immunol 1997; 158: 3836-3844.
29. Eltzschig HK, Eckle T. Ischaemia and reperfusion-from mechanism to translation. Nat Med 2011; 17: 1391-1401.
30. Kukielka GL, Smith CW, Manning AM, et al. Induction of interleukin-6 synthesis in the myocardium. Potential role in postreperfusion inflammatory injury. Circulation 1995; 92: 1866-1875.
31. Kukielka GL, Smith CW, LaRosa GJ, et al. Interleukin-8 gene induction in the myocardium after ischaemia and reperfusion in vivo. J Clin Invest 1995; 95: 89-103.
32. Kivikko M, Lehtonen L, Colucci WS. Sustained haemodynamic effects of intravenous levosimendan. Circulation 2003; 107: 81-86.
33. Zhao ZQ, Lefer DJ, Sato H, et al. Monoclonal antibody to ICAM-1 preserves postischaemic blood flow and reduces infarct size after ischaemia-reperfusion in rabbit. J Leukoc Biol 1997; 62: 292-300.
34. Ma XL, Tsao PS, Lefer AM. Antibody to CD-18 exerts endothelial and cardiac protective effects in myocardial ischaemia and reperfusion. J Clin Invest 1991; 88: 1237-1243.
35. Ghosh CC, Ramaswami S, Juvekar A, et al. Gene-specific repression of proinflammatory cytokines in stimulated human macrophages by nuclear IkappaBalpha. J Immunol 2010; 185: 3685-3693.
36. Kivikko M, Antila S, Eha J, et al. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Therapeut 2002; 40: 465-471.